This cost-effectiveness analysis of data from the FLAURA randomized clinical trial evaluates the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year of osimertinib as a first-line treatment for patients with EGFR-mutated advanced non–small cell lung cancer in the United States and Brazil.
https://ift.tt/2JfHF0H
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
-
Duraisamy Balaguru, Matthew Rodriguez, Stephanie Leon, Louis K Wagner, Charles W Beasley, Andrew Sultzer, Mohammed T Numan Annals of P...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου